Etretinate and pregnancy.
作者信息
Lammer E
出版信息
Lancet. 1989 Jan 14;1(8629):109. doi: 10.1016/s0140-6736(89)91473-6.
PMID:2562875
Abstract
摘要
相似文献
1
Etretinate and pregnancy.依曲替酯与妊娠
Lancet. 1989 Jan 14;1(8629):109. doi: 10.1016/s0140-6736(89)91473-6.
2
Embryopathy in infant conceived one year after termination of maternal etretinate: a reappraisal.母亲异维甲酸停药一年后受孕婴儿的胚胎病：重新评估。
Lancet. 1988 Nov 26;2(8622):1254.
3
Embryopathy in infant conceived one year after termination of maternal etretinate.
Lancet. 1988 Nov 5;2(8619):1080-1. doi: 10.1016/s0140-6736(88)90101-8.
4
[Embryonal malformation following etretinate therapy of Darier's disease in the mother].[母亲服用阿维A酯治疗毛囊角化病后出现胚胎畸形]
Dtsch Med Wochenschr. 1986 Jan 10;111(2):60-2. doi: 10.1055/s-2008-1068402.
5
Malformation of fetus conceived 4 months after termination of maternal etretinate treatment.母亲阿维A酯治疗终止4个月后受孕胎儿的畸形。
Lancet. 1985 Jun 1;1(8440):1276. doi: 10.1016/s0140-6736(85)92344-x.
6
Teratogenicity of isotretinoin and etretinate.异维A酸和阿维A酯的致畸性。
Lancet. 1988 Nov 12;2(8620):1143. doi: 10.1016/s0140-6736(88)90564-8.
7
Etretinate embryotoxicity 7 months after discontinuation of treatment.
Am J Med Genet. 1990 Nov;37(3):437-8. doi: 10.1002/ajmg.1320370333.
8
[Teratogenic effects of etretinate in humans].[维甲酸对人类的致畸作用]
Dtsch Med Wochenschr. 1984 Sep 28;109(39):1476-80. doi: 10.1055/s-2008-1069397.
9
Teratogenic risk with etretinate and acitretin treatment.阿维A酯和阿维A治疗的致畸风险。
Dermatology. 1994;189(2):109-16. doi: 10.1159/000246811.
10
Etretinate approved.依曲替酯已获批。
FDA Drug Bull. 1986 Nov;16(2):16-7.
引用本文的文献
1
Risk classification systems for drug use during pregnancy: are they a reliable source of information?孕期药物使用风险分类系统：它们是可靠的信息来源吗？
Drug Saf. 2000 Sep;23(3):245-53. doi: 10.2165/00002018-200023030-00006.
Zotero 插件